返回 
加入收藏
药品生产企业核心竞争力的定义与其评价体系构建
x
请在关注微信后，向客服人员索取文件
| 篇名： | 药品生产企业核心竞争力的定义与其评价体系构建 |
| TITLE： | Definition of Core Competitiveness of Drug Manufacturing Enterprises and Construction of Its Evaluation System |
| 摘要： | 目的：定义药品生产企业核心竞争力，并构建其评价体系。方法：以“核心竞争力“”医药”为中文关键词“，Corecompeti-tiveness”“Pharmaceutical”为英文关键词，检索（自建立/建库至2020年6月，下同）发布在中国相关政府网站中的法规政策和解读文件，以及在PubMed、Embase、中国生物医学文献数据库、万方数据、中国期刊全文数据库和维普网等中发表的相关文献，利用循证研究方法定义药品生产企业核心竞争力和构成要素；基于上述构成要素和检索手段并补充检索指南数据库（NationalGuidelineClearinghouse、GuidelinesInternationalNetwork、Tripdatabase、TheNationalInstituteforHealthandCareExcellence）和系统评价、卫生技术评估、卫生经济学评价研究数据库（NHSEconomicEvaluationDatabase、TheCochraneLibrary、HTA等），提取药品生产企业核心竞争力的产出指标，并依据科学性、层次性、可比性、综合性原则，构建药品生产企业核心竞争力的评价体系。结果与结论：药品生产企业核心竞争力的定义拟定为企业所具有的着眼国家战略需求，主动承接国家重大科技项目，引进国内外顶尖科技人才，具有自主知识产权，提升科技支撑能力，强化原始创新，增加研发投入，加强关键核心技术攻关，健全以企业为主体的产学研一体化创新机制等方面的创新型企业能力；其构成要素为原始创新、研发投入和科技人才。共提取出25个原始创新产出指标[包括创新体系（如国家级科技创新基地、国家实验室等）、创新成果（如国家自然科学奖、国家技术发明奖等）两个方面]，1个研发投入产出指标（研发金额），7个生产企业科技人才产出指标（如“国家百千万人才工程”入选者“、全国杰出科技人才”奖得主等），构建了以原始创新、研发投入和科技人才为构成要素的评价体系，可为客观评价药品生产企业核心竞争力提供依据。 |
| ABSTRACT： | OBJECTIVE：To define the core competitiveness of drug manufacturing enterprises ，and build its evaluation system. METHODS ：With“core competitiveness ”and“pharmaceutical”as Chinese and English keywords ，the laws ，policies and interpretation documents published on relevant Chinese government websites （from the inception/establishment of the database to June 2020，the same below ）were retrieved. Related literatures were collected from PubMed ，Embase，CBM，Wanfang database ， CNKI，VIP databases. The evidence-based research method was adopted to define the core competitiveness and elements of drug manufacturing enterprises. Based on above elements and retrieval method ，guideline database （National Guideline Clearinghouse ， Guidelines International Network ，Trip database ，The National Institute for Health and Care Excellence ）and systematic review ， health technology assessment （HTA），health economics evaluation research databases （NHS Economic Evaluation Database ，the Cochrane Library ，HTA，etc.）were retrieved. The output indexes of the core competitiveness of drug manufacturing enterprises were extracted ；according to the principles of scientificity ，hierarchy，comparability and comprehensiveness ，the evaluation system of core competitiveness of drug manufacturing enterprises was constructed. RESULTS & CONCLUSIONS ：The definition of core competitiveness of drug manufacturers is proposed as the strategic needs of the enterprises ，actively undertaking major national science and technology projects ，introducing top scientific and technological talents at home and abroad ，having independent intellectual property rights ，enhancing the ability of scientific and technological support ，strengthening original innovation ， increasing R&D investment ， strengthening key technology breakthrough ， perfecting the innovation mechanism of enterprises-univerisities-researches integration with enterprises as the main body. The elements included original innovation ， 60362951。 R&D investment and scientific and technological talents. Atotal of 25 original innovation output indexes [including two aspects of innovation system （such as national science and technology innovation base ，national laboratory ），innovation achievements （such as National Natural Science Award ， National Technological Invention Award ）]，1 R&D input-output indicator （R&D amount ），7 scientific and technological talent output indicators of production enterprises （such as those selected in the “National Million Talent Project ”，“National Outstanding Scientific and Technological Talents ”award） were extracted. The evaluation system composed of original innovation ，R&D investment and scientific and technological talents is constructed ，which can provide objective evaluation for core competitiveness of pharmaceutical manufacturing enterprises. |
| 期刊： | 2021年第32卷第07期 |
| 作者： | 彭龙希，李蒙，杨圆圆，李正翔，段蓉 |
| AUTHORS： | PENG Longxi，LI Meng，YANG Yuanyuan，LI Zhengxiang，DUAN Rong |
| 关键字： | 核心竞争力；原始创新；研发投入；科技人才；循证研究；药品生产企业 |
| KEYWORDS： | Core competitiveness ；Original innovation ；R&D investment ；Technology talents ；Evidence-based research ；Drug |
| 阅读数： | 232 次 |
| 本月下载数： | 8 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
